JP2017530092A5 - - Google Patents

Download PDF

Info

Publication number
JP2017530092A5
JP2017530092A5 JP2017504375A JP2017504375A JP2017530092A5 JP 2017530092 A5 JP2017530092 A5 JP 2017530092A5 JP 2017504375 A JP2017504375 A JP 2017504375A JP 2017504375 A JP2017504375 A JP 2017504375A JP 2017530092 A5 JP2017530092 A5 JP 2017530092A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
molecule
antibody molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017504375A
Other languages
English (en)
Japanese (ja)
Other versions
JP6577016B2 (ja
JP2017530092A (ja
Filing date
Publication date
Priority claimed from GBGB1413357.3A external-priority patent/GB201413357D0/en
Application filed filed Critical
Publication of JP2017530092A publication Critical patent/JP2017530092A/ja
Publication of JP2017530092A5 publication Critical patent/JP2017530092A5/ja
Application granted granted Critical
Publication of JP6577016B2 publication Critical patent/JP6577016B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017504375A 2014-07-28 2015-07-28 治療及び診断のための抗コラーゲン抗体 Expired - Fee Related JP6577016B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1413357.3A GB201413357D0 (en) 2014-07-28 2014-07-28 Antibodies for treatment and diagnosis
GB1413357.3 2014-07-28
PCT/EP2015/067314 WO2016016269A1 (en) 2014-07-28 2015-07-28 Anti-collagen antibodies for treatment and diagnosis

Publications (3)

Publication Number Publication Date
JP2017530092A JP2017530092A (ja) 2017-10-12
JP2017530092A5 true JP2017530092A5 (https=) 2019-04-18
JP6577016B2 JP6577016B2 (ja) 2019-09-18

Family

ID=51587356

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017504375A Expired - Fee Related JP6577016B2 (ja) 2014-07-28 2015-07-28 治療及び診断のための抗コラーゲン抗体
JP2017504376A Pending JP2017526654A (ja) 2014-07-28 2015-07-28 治療及び診断のための抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017504376A Pending JP2017526654A (ja) 2014-07-28 2015-07-28 治療及び診断のための抗体

Country Status (6)

Country Link
US (2) US10098976B2 (https=)
EP (2) EP3174899A1 (https=)
JP (2) JP6577016B2 (https=)
CA (1) CA2992136C (https=)
GB (1) GB201413357D0 (https=)
WO (2) WO2016016265A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7626577B2 (ja) 2016-11-28 2025-02-07 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
BR112019008727A2 (pt) 2016-11-28 2019-07-16 Chugai Seiyaku Kabushiki Kaisha domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte
CA3047312A1 (en) * 2016-12-15 2018-06-21 The Brigham And Women's Hospital, Inc. Tissue-based biologics for the treatment of inflammatory and autoimmune disorders
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
WO2018153865A1 (en) * 2017-02-24 2018-08-30 Philogen S.P.A. Immunoconjugates with optimized linkers and orientation
US11732029B2 (en) * 2017-11-13 2023-08-22 The University Chicago Methods and compositions for the treatment of wounds
JP7482630B2 (ja) 2017-11-28 2024-05-14 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
WO2019183131A1 (en) * 2018-03-19 2019-09-26 Bioventures, Llc Periostin antibodies and methods of using the same
EP3775258A4 (en) 2018-03-28 2022-01-26 Board of Regents, The University of Texas System IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES
JP7414736B2 (ja) * 2018-05-30 2024-01-16 中外製薬株式会社 アグリカン結合ドメインおよび運搬部分を含むポリペプチド
BR112020026819A2 (pt) * 2018-06-29 2021-04-20 Alector Llc anticorpos isolados, ácido nucleico, vetor, células hospedeiras, método de produção de um anticorpo, composição farmacêutica, métodos para tratar o câncer e para tratar uma doença e usos de um anticorpo
CN114641310A (zh) * 2019-06-21 2022-06-17 德克萨斯大学系统董事会 治疗癌症和其他疾病的靶向α3β1整合素
BR112022001985A2 (pt) * 2019-09-11 2022-05-10 Boehringer Ingelheim Io Canada Inc Métodos para tratamento de câncer pelo uso de inibidores do eixo pd-1 e anticorpos anti-periostina

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541295A (en) 1993-02-12 1996-07-30 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Detection of type II collagen and its peptides
ES2333845T3 (es) 1999-01-06 2010-03-02 University Of Southern California Metodo y composicion para la inhibicion de la angiogenesis.
US7824680B2 (en) * 2001-08-06 2010-11-02 The Regents Of The University Of California Methods for inhibiting angiogenesis
GB0207224D0 (en) * 2002-03-27 2002-05-08 Novartis Forschungsstiftung Tenascin-W compositions and uses thereof
GB0708585D0 (en) * 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
KR20120064072A (ko) 2009-09-16 2012-06-18 시오노기세야쿠 가부시키가이샤 콜라겐 네오에피토프 항체
ES2757857T3 (es) * 2010-09-27 2020-04-30 Janssen Biotech Inc Anticuerpos de unión a colágeno II humano

Similar Documents

Publication Publication Date Title
JP2017530092A5 (https=)
JP2013121353A5 (https=)
HRP20201975T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
HRP20200882T1 (hr) Vezujuće molekule specifične za asct2 i njihova uporaba
FI3487882T3 (fi) Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja
JP2010534237A5 (https=)
NZ602040A (en) Anti-lrp6 antibodies
JP2010523541A5 (https=)
JP2011502137A5 (https=)
HRP20180352T1 (hr) Protutijela anti-fcrh5
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
HRP20220811T1 (hr) Agonistička sredstva za vezanje tnf receptora
HRP20201022T1 (hr) Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
HRP20191678T1 (hr) Pd-1 protutijelo, njegov fragment koji se veže na antigen, i njegova medicinska primjena
HRP20221088T1 (hr) Protutijela i postupci uporabe
HRP20201064T1 (hr) Postupci liječenja tauopatije
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
JP2017535257A5 (https=)
HRP20211444T1 (hr) Anti-dll3 antitijelo
JP2016135783A5 (https=)
HRP20180015T1 (hr) Anti-mezotelinski imunokonjugati i njihova uporaba
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
PE20150211A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
EA201391159A1 (ru) Hla-рестриктированные пептидоспецифические антигенсвязывающие белки
JP2012010714A5 (https=)